Oral Solid Dosage Manufacturing: Schedule M Controls

In short: This guide summarizes India’s revised Schedule M requirements for manufacturing tablets and capsules. It is for production, quality assurance and quality control staff; the main controls address dust and mix-up prevention, documented process settings, in-process checks and packaging integrity.

Scope and current reference

The current Indian requirements are in revised Schedule M under the Drugs Rules, 1945, notified by G.S.R. 922(E) on 28 December 2023. G.S.R. 666(E), dated 25 October 2024, corrected the notification’s short title and a reference in its note. The tablet and capsule requirements summarized below are in Part I. The older label “Revised Schedule M4” is not the name of this current instrument.

Powder handling and equipment

Unless the operation is closed, sifting, mixing and blending equipment must have dust extraction or be placed in a dedicated area. Sieving residues are examined periodically for unwanted material. Critical mixing, blending and drying parameters, including time and temperature, belong in the Master Formula and must be monitored and recorded in batch records.

For fluid-bed dryers, filter bags are washed between products; certain highly potent or sensitising products require product-specific bags. Inlet air is filtered, and the exhaust arrangement must control dust release. Granulation and coating solutions are prepared, stored and used to reduce contamination and microbial-growth risks. (Revised Schedule M, Part I §§2.1–2.5, G.S.R. 922(E), 2023.)

Tablet compression controls

Compression equipment needs effective dust control. Separate cubicles are required unless the same product is being made on each machine or the machine provides its own enclosed, air-controlled environment. Physical, procedural and labelling controls must prevent mix-ups. Calibrated weighing equipment is used for weight-variation checks, with procedures able to detect tablets outside their limits.

At the start of a compression run and at fixed intervals, sampling must cover each compression station or point for the specified checks. The results form part of the batch record. Tablets are de-dusted and checked for foreign matter or other defects, collected in clean labelled containers, and rejected units are isolated with their quantities recorded.

During compression, tablet samples must also be taken at intervals of not more than 30 minutes to confirm compliance with in-process specifications. Other checks named in Schedule M include appearance, weight variation, disintegration, hardness, friability, thickness and possible lubricating-oil contamination. (Revised Schedule M, Part I §§3.1–3.8, G.S.R. 922(E), 2023.)

Coating, capsules and printing

Drying air supplied to coating pans must be filtered and suitable for use. The area needs an appropriate exhaust system and environmental controls for temperature and humidity. Coating solutions and suspensions are made fresh, handled to limit microbial-growth risk, and their preparation and use are recorded. Empty hard-gelatin capsule shells are treated as drug components and stored to protect them from excessive heat and moisture.

Printing controls must prevent product mix-ups. If products or batches are printed at the same time, the operations are segregated. Quality Control approval is required after printing and before the tablets or capsules move to packaging or sale. (Revised Schedule M, Part I §§4.1–4.2, 5 and 6.1–6.2, G.S.R. 922(E), 2023.)

Strip and blister packaging

Before a new packaging operation, the line is checked for leftover tablets, capsules and foils; an independent check is recorded before a new batch is handled. Uncoated tablets are packed on equipment designed to reduce cross-contamination, with isolated-area packing specified for potent or beta-lactam tablets. Finished strips are inspected for issues such as misprinting, foil cuts, missing tablets and poor seals. Strip and blister integrity is checked by vacuum testing periodically, and the results are recorded. (Revised Schedule M, Part I §§7.1–7.4, G.S.R. 922(E), 2023.)

Batch records and retention

Record processing activities as they occur so that significant manufacturing steps are traceable. India’s revised Schedule M requires records to be retained for at least one year after the finished product’s expiry date (Part I §17.2.7, G.S.R. 922(E), 2023). For EU batch documentation, EudraLex Volume 4, Part I, Chapter 4 §4.11 (January 2011) specifies one year after expiry or five years after Qualified Person certification, whichever is longer. In the United States, 21 CFR Part 211 §211.180(a) specifies one year after batch expiry, with a separate three-year rule for certain OTC products exempt from expiry dating. Apply any longer requirement in the applicable law or marketing authorisation.

For related procedures, see operation and cleaning of a tablet compression machine, compression-stage quality attributes and GMP controls for pharmaceutical capsules.

Frequently asked questions

Is the 30-minute tablet sampling interval an in-house practice?

No. Revised Schedule M Part I §3.8 says compression samples are taken at regular intervals of not more than 30 minutes to check in-process compliance.

Does every tablet compression machine need its own cubicle?

Part I §3.1 provides exceptions when the same product is made on each machine or when the compression machine itself provides an enclosed, air-controlled environment.

How often must blister packs be vacuum tested?

Part I §7.4 requires periodic vacuum testing and records, but does not specify a universal numerical interval in that clause. Follow the approved, applicable procedure for the product and packaging line.

How long are production records kept?

Schedule M Part I §17.2.7 requires at least one year after the finished product’s expiry date. Other jurisdictions or product authorisations may require longer retention.

References

• Government of India, Ministry of Health and Family Welfare, Drugs (Second Amendment) Rules, 2023, G.S.R. 922(E), 28 December 2023; revised Schedule M, Part I §§2.1–2.5, 3.1–3.8, 4.1–4.2, 5, 6.1–6.2, 7.1–7.4 and 17.2.7. Official CDSCO Gazette PDF
• Government of India, Ministry of Health and Family Welfare, corrigendum to G.S.R. 922(E), G.S.R. 666(E), 25 October 2024. Official CDSCO Gazette PDF
• European Commission, EudraLex Volume 4, EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Part I, Chapter 4: Documentation, January 2011, §4.11. Official PDF
• United States, 21 CFR Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals, §211.180(a), eCFR current as of 14 October 2026. Official eCFR text